Breaking News: Atea Pharmaceuticals Receives Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
Embracing Change: Atea Pharmaceuticals’ Unsolicited Proposal The Unexpected Offer On May 23, 2023, Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) was surprised to receive an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC. The proposal outlined an offer to acquire all outstanding common shares of Atea for $5.75 per share in cash, along…